All Oncology News

BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.

Dostarlimab monotherapy produced a 27% response rate in PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma

Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.

The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.

Huntsman Cancer Institute received recent national honors, recognizing excellence in cancer care, research, nursing, and healing-centered facilities.

Marc S. Hoffmann, MD, discusses data for sonrotoclax plus zanubrutinib and unmet needs in the mantle cell lymphoma treatment paradigm.

PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.

Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.

Colorectal cancer is not the only gastrointestinal cancer that doctors are diagnosing in patients below the age of 50.

Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Top experts discuss the most important takeaways and data in ovarian and endometrial cancer to come out of this year’s ASCO annual meeting.

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

New insights on early detection, cancer biology and surgical innovation in head and neck cancer highlighted at international research meeting.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

A rituximab biosimilar has been approved by the FDA.

Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.

Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.

First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.